A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
暂无分享，去创建一个
J. Ritz | S. Nikiforow | P. Armand | R. Soiffer | B. Blazar | C. Cutler | Haesook T. Kim | J. Antin | V. Ho | E. Alyea | C. Reynolds | J. Koreth | B. Glotzbecker | B. Bindra | Paulina B. Lange | Marie J Chammas | Carol G. Reynolds